CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- 4 Open-market sale Chief Scientific Officer sold 6,500 shares at an average $15.29 ($99,397)
- 10-K Report Annual Report
- 8-K Event Material agreement · Results of operations · New debt or obligation · Unregistered share sale · Other events
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Option exercise Director acquired 8,124 shares (option exercise)
- 4 Open-market sale Chief Scientific Officer sold 2,000 shares at $15.02 ($30,040)
- 8-K Event Other events
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- 8-K Event Other events
- 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $21.47 ($91,252)
- 4 Option exercise Chief Scientific Officer acquired 16,000 shares (option exercise)
- UPLOAD Other SEC-generated Letter
- 8-K Event Material agreement
- S-3 Offering Registration Statement
- 8-K Event Other events
- 8-K Event Other events
- 4 Open-market sale Chief Scientific Officer sold 11,333 shares at an average $29.49 ($334,197)
- 4 Open-market sale President and CEO sold 400 shares at $31.75 ($12,700)
Page 39 of 47 · 923 filings